“…Test agents used included a synthetic glucocorticoid, Dex (Sigma-Aldrich, St. Louis, MO); a selective glucocorticoid type II receptor antagonist (Clapham and Turner, 1997;Limbourg et al, 2002), mifepristone (RU486; SigmaAldrich), that does not bind to the type I mineralocorticoid receptor or to aldosterone receptors (Brogden et al, 1993); a selective GABA A receptor antagonist (Galvez-Ruano et al, 1995), bicuculline methiodine (Sigma-Aldrich); a GABA B receptor antagonist (Al-Dahan et al, 1990), 2-hydroxy saclofen (2-OH saclofen; Sigma-Aldrich); a nonselective nitric-oxide synthase (NOS) inhibitor (Reif and McCreedy, 1995), N G -monomethyl-L-arginine acetate (L-NMMA; SigmaAldrich); a PI3K inhibitor (Vlahos et al, 1994), LY294002 (Calbiochem, San Diego, CA); and an RNA synthesis inhibitor , actinomycin D (AMD; Calbiochem). The dose and treatment scheme were adopted from previous reports (Clapham and Turner, 1997;Ouyang and Wang, 2000;Hafezi-Moghadam et al, 2002;Limbourg et al, 2002;Moreno et al, 2002;Chan et al, 2003), which used the same test agents for the same purpose as in this study. With the exception of mifepristone, LY294002, and AMD, which used, respectively, 1 or 0.2% DMSO or 3% methanol as the solvent, all test agents were prepared with aCSF.…”